The EMA said it made this decision after analyzing the results of a study of more than 5,000 people.
Article written by
Posted
Update
Reading time : 1 min.
The European Medicines Agency (EMA) recommended, Thursday, March 24, the marketing, for those over 12 years old “weighing at least 40 kg”, of AstraZeneca’s preventive treatment against Covid-19, Evusheld. This treatment is intended for people who lack antibodies and whose body is resistant to vaccination. Evusheld combines two types of synthetic antibodies (tixagevimab and cilgavimab) and is administered as two intramuscular injections. It is particularly considered effective against the Omicron variant.
These antibodies help the immune system fight off the virus if it is encountered, by targeting its Spike protein, which allows it to enter cells to infect them. The European regulator assured that it had taken this decision after analyzing the results of a study on more than 5,000 people. “Evusheld’s safety profile was favorable and side effects were generally mild, with a small number of people experiencing reactions”explained the EMA in a press release.
The European Medicines Agency has concluded that the benefits of the treatment outweigh its risks. She will now send her recommendation to the European Commission for a quick decision applicable in all EU member states.